{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:29Z","timestamp":1793291609986,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Inflammation contributes to the pathophysiology of heart failure (HF), yet the global prevalence of elevated high sensitivity C-reactive protein (hsCRP) in patients with HF across the ejection fraction (EF) spectrum remains unclear. We sought to characterize the prevalence and clinical correlates of high inflammatory risk (defined as hsCRP \u22652\u2005mg\/L) in a global real-world HF cohort across the EF spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>POSEIDON prospectively enrolled 18 904 individuals across 317 sites in 18 countries (2023\u201325) at routine visits, including 11 809 with HF and available hsCRP (3714 with preserved EF [HFpEF], 2176 with mildly reduced EF [HFmrEF], 5919 with reduced EF [HFrEF]), and excluding those with recent infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated hsCRP (\u22652\u2005mg\/L) was found in 1442 (38.8%) patients with HFpEF, 830 (38.1%) with HFmrEF, and 2263 (38.2%) with HFrEF. Within each HF subtype, patients with elevated hsCRP were more likely to be female and to have chronic kidney disease, obesity, worse functional class, and higher N-terminal pro-B-type natriuretic peptide levels. In multivariable analyses, independent predictors of elevated hsCRP included smoking, rheumatic\/autoimmune\/inflammatory disease, obesity, reduced eGFR, dyslipidaemia and worse NYHA class. These predictors were consistent across HF subtypes (interaction P &amp;gt; .05), except body mass index, which was more strongly associated with hsCRP in HFpEF (interaction P = .001). Interleukin-6 correlated moderately with hsCRP across all HF subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a global HF population, high inflammatory risk is present in approximately 4 in 10 patients and is associated with more severe HF and a cardio-kidney-metabolic phenotype. These findings were consistent across HF subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag155","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:37:11Z","timestamp":1778153831000},"source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and predictors of high inflammatory risk in heart failure subtypes: findings from the global POSEIDON study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S P","family":"Lam","sequence":"first","affiliation":[{"name":"National Heart Centre Singapore , 5 Hospital Drive, Singapore 169609 ,","place":["Singapore"]},{"name":"Duke-National University of Singapore , 8 College Road, Singapore 169857 ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Contreras","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplant Cardiology, Department of Medicine, Division of Cardiology, Mount Sinai School of Medicine, Mount Sinai Fuster Heart Hospital , NewYork, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Darwesh","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aguinaldo F","family":"Freitas Junior","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s Faculty of Medicine, , Goi\u00e2nia ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lund","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine , Nagano ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Ludman","sequence":"additional","affiliation":[{"name":"Royal Devon University Healthcare NHS Foundation Trust , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-5957","authenticated-orcid":false,"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Mathisen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Nelson","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Victorian Heart Institute, Monash University , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine, Angiology and Arteriosclerosis Diseases, University of Perugia , Perugia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Ren","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Max Rady College of Medicine, University of Manitoba , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen Faculty of Medical Sciences, , Hanzeplein 1, Groningen 9713 GZ ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"2026051501365626400_xuag155-B1","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-023-02567-2","article-title":"Recent successes in heart failure treatment","volume":"29","author":"Lam","year":"2023","journal-title":"Nat Med"},{"key":"2026051501365626400_xuag155-B2","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026051501365626400_xuag155-B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026051501365626400_xuag155-B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026051501365626400_xuag155-B5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051501365626400_xuag155-B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026051501365626400_xuag155-B7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026051501365626400_xuag155-B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026051501365626400_xuag155-B9","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","article-title":"Endotoxin and immune activation in chronic heart failure: a prospective cohort study","volume":"353","author":"Niebauer","year":"1999","journal-title":"Lancet"},{"key":"2026051501365626400_xuag155-B10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026051501365626400_xuag155-B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201836","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction","volume":"13","author":"DuBrock","year":"2018","journal-title":"PLoS One"},{"key":"2026051501365626400_xuag155-B12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41569-023-00919-6","article-title":"Immunomodulation and immunopharmacology in heart failure","volume":"21","author":"Markousis-Mavrogenis","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026051501365626400_xuag155-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131818","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT","volume":"402","author":"Ferreira","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026051501365626400_xuag155-B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102712","article-title":"Prevalence and associations of systemic inflammation in heart failure across the spectrum of ejection fraction","volume":"14","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026051501365626400_xuag155-B15","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/ejhf.3452","article-title":"Burst steroid therapy for acute heart failure: the CORTAHF randomized, open-label, pilot trial","volume":"26","author":"Cotter","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051501365626400_xuag155-B16","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1093\/eurheartj\/ehae538","article-title":"Colchicine in acutely decompensated heart failure: the COLICA trial","volume":"45","author":"Pascual-Figal","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051501365626400_xuag155-B17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10741-025-10491-5","article-title":"Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis","volume":"30","author":"Davison","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026051501365626400_xuag155-B18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051501365626400_xuag155-B19","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026051501365626400_xuag155-B20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study","volume":"142","author":"Sanders-van Wijk","year":"2020","journal-title":"Circulation"},{"key":"2026051501365626400_xuag155-B21","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026051501365626400_xuag155-B22","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026051501365626400_xuag155-B23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051501365626400_xuag155-B24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051501365626400_xuag155-B25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051501365626400_xuag155-B26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"2026051501365626400_xuag155-B27","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"2026051501365626400_xuag155-B28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","journal-title":"Lancet"},{"key":"2026051501365626400_xuag155-B29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"IL6R Genetics Consortium Emerging Risk Factors Collaboration","year":"2012","journal-title":"Lancet"},{"key":"2026051501365626400_xuag155-B30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2026051501365626400_xuag155-B31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026051501365626400_xuag155-B32","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag155\/68259397\/xuag155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag155\/68259397\/xuag155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:37:05Z","timestamp":1778823425000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag155\/8674958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag155","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"article-number":"xuag155"}}